Can a Dual-Pronged antibody outsmart advanced cancers?

NCT ID NCT07753226

First seen Aug 07, 2026 ยท Last updated Aug 07, 2026

Summary

This early-stage trial is testing an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in people with locally advanced or metastatic breast cancer and other solid tumors. The study aims to find the safest dose and understand how the drug behaves in the body, while also looking for early signs that it can shrink tumors. Participants receive the drug by intravenous infusion over a three-week cycle, and the trial will closely monitor side effects and any antitumor activity.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
SI-B036, a bispecific antibody given by intravenous infusion
What this could lead to
If successful, this could lead to a new treatment option for advanced breast cancer and other solid tumors, potentially slowing disease progression.
What could go wrong
This is an early-phase trial with a small number of participants, so the drug may not be effective or may cause significant side effects. The results will not be known until the study is complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.